SEC 13F Intelligence

Managers / Q4 2023 · view latest →

Altium Capital Management LLC

CIK 0001746382 · 152 W 57 ST FL7, NEW YORK, NY, 10019 · 2124842711

Reported Value
$147M
Q4 2023
Positions
66
Filings on Record
25
2019–present window
Filed
Feb 14, 2024
original filing

Summary

Altium Capital Management LLC reported $147M in U.S.-listed holdings across 66 positions for Q4 2023.

Its largest position, XENE, represents 9.1% of the portfolio.

Compared with Q3 2023, the fund opened 23 new positions and exited 29.

Portfolio Metrics

Turnover
+45.5%
vs prior filed quarter
Top-10 Concentration
+60.3%
share of reported value
Largest Position
+9.1%
Xenon Pharmaceuticals
New / Exited
23 / 29
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $266MQ4 ’20Q1 ’21: $360MQ2 ’21: $431MQ3 ’21: $381MQ3 ’21Q4 ’21: $363MQ1 ’22: $299MQ2 ’22: $250MQ2 ’22Q3 ’22: $273MQ4 ’22: $197MQ1 ’23: $180MQ1 ’23Q2 ’23: $132MQ3 ’23: $192MQ4 ’23: $147MQ4 ’23Q1 ’24: $253MQ2 ’24: $245MQ3 ’24: $340MQ3 ’24Q4 ’24: $353MQ1 ’25: $42MQ2 ’25: $0Q2 ’25Q3 ’25: $628,262Q4 ’25: $25MQ1 ’26: $42MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 81.4%Other: 10.7%ETP: 7.0%Equity WRT: 0.6%ADR: 0.3%
  • Common Stock · 81.4% · $120M
  • Other · 10.7% · $16M
  • ETP · 7.0% · $10M
  • Equity WRT · 0.6% · $848,315
  • ADR · 0.3% · $447,408

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
EA SERIES TRUSTNEW+92.7K92.7K+$10M$10M
CN2CATALYST PHARMACEUTICALS INCNEW+385.0K385.0K+$6M$6M
SVRASAVARA INCNEW+1.33M1.33M+$6M$6M
INSMINSMED INCNEW+120.0K120.0K+$4M$4M
IMVTIMMUNOVANT INCNEW+80.0K80.0K+$3M$3M
ASNDASCENDIS PHARMA A/SNEW+25.0K25.0K+$3M$3M
ENVVENO MEDICAL CORPORATIONNEW+344.5K344.5K+$2M$2M
CYTKCYTOKINETICS INCNEW+20.0K20.0K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

63 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1XENEXENON PHARMACEUTICALS INChistory →COM9.08%$13M290.5K
2ALIMERA SCIENCES INCCOM NEW7.80%$11M2.66M
3AXSMAXSOME THERAPEUTICS INChistory →COM7.46%$11M138.0K
4EA SERIES TRUSTALPHA ARCH 1-36.62%$10M92.7K
5VERAVERA THERAPEUTICS INChistory →CL A6.42%$9M615.0K
6XTNTXTANT MED HLDGS INChistory →COM NEW6.16%$9M8.03M
7CN2CATALYST PHARMACEUTICALS INChistory →COM4.39%$6M385.0K
8SVRASAVARA INChistory →COM4.25%$6M1.33M
9ORICORIC PHARMACEUTICALS INChistory →COM4.22%$6M676.0K
10OLMAOLEMA PHARMACEUTICALS INChistory →COM3.94%$6M413.6K
11ASTRIA THERAPEUTICS INCCOM3.81%$6M730.0K
12INTRA-CELLULAR THERAPIES INCCOM3.45%$5M71.0K
13ADMAADMA BIOLOGICS INChistory →COM3.36%$5M1.09M
14SOLENO THERAPEUTICS INCCOM2.87%$4M104.9K
15INSMINSMED INChistory →COM PAR $.012.52%$4M120.0K
16IMVTIMMUNOVANT INChistory →COM2.29%$3M80.0K
17ASNDASCENDIS PHARMA A/Shistory →SPONSORED ADR2.14%$3M25.0K
18CYMABAY THERAPEUTICS INCCOM1.78%$3M111.0K
19SGMTSAGIMET BIOSCIENCES INChistory →COM SER A1.72%$3M483.2K
20CRNXCRINETICS PHARMACEUTICALS INhistory →COM1.57%$2M65.0K
21MARINUS PHARMACEUTICALS INCCOM NEW1.48%$2M200.0K
22ENVVENO MEDICAL CORPORATIONCOM1.20%$2M344.5K
23AMLXAMYLYX PHARMACEUTICALS INChistory →COM1.19%$2M119.5K
24CYTKCYTOKINETICS INChistory →COM NEW1.13%$2M20.0K
25ALPINE IMMUNE SCIENCES INCCOM1.02%$2M78.7K
26VERU INCCOM0.98%$1M2.00M
27NGNENEUROGENE INCCOM0.88%$1M67.0K
28ARVNARVINAS INCCOM0.87%$1M31.2K
29FBIOFORTRESS BIOTECH INCCOM NEW0.83%$1M405.1K
30DMACDIAMEDICA THERAPEUTICS INCCOM NEW0.55%$817,062287.7K
31FAT BRANDS INC*W EXP 07/16/2020.46%$680,000200.0K
32KARYOPHARM THERAPEUTICS INCCOM0.43%$640,100740.0K
33MSOSADVISORSHARES TRPURE US CANNABIS0.38%$560,80080.0K
34DDIDOUBLEDOWN INTERACTIVE CO LTADS0.30%$447,40860.9K
35RYTMRHYTHM PHARMACEUTICALS INCCOM0.20%$298,1156.5K
36FLNACASSAVA SCIENCES INCCOM0.20%$292,63013.0K
37TONIX PHARMACEUTICALS HLDG CCOM NEW0.15%$217,630540.0K
38NXGLWNEXGEL INC*W EXP 12/01/2020.07%$110,250225.0K
39CYCLACEL PHARMACEUTICALS INCCOM NEW0.07%$101,41238.0K
40WEARABLE DEVICES LTD*W EXP 09/14/2020.07%$98,8121.41M
41NOCTURNE ACQUISITION CORPRIGHT 12/26/20250.06%$82,400500.0K
42SADOT GROUP INCCOM0.05%$67,378168.2K
43ONFOWONFOLIO HOLDINGS INC*W EXP 01/02/2020.01%$16,000200.0K
44NOVABAY PHARMACEUTICALS INCCOM0.01%$13,76167.5K
45NLS PHARMACEUTICS LTD*W EXP 02/02/2020.01%$11,220200.0K
46PEPPERLIME HEALTH ACQUSTN CO*W EXP 10/01/2020.01%$11,062367.5K
47MOBIX LABS INC*W EXP 12/21/2020.01%$10,530150.0K
48CINGWCINGULATE INC*W EXP 12/10/2020.01%$8,100270.0K
49BTMWQBITCOIN DEPOT INC*W EXP 06/30/2020.00%$7,25050.0K
50CONDUIT PHARMACEUTICALS INC*W EXP 09/22/2020.00%$6,930100.0K
51PROSOMNUS INC*W EXP 04/20/2020.00%$4,260150.0K
52DIGITAL HEALTH ACQUISITION C*W EXP 11/02/2020.00%$3,908150.0K
53CYCUWWESTERN ACQSTN VENTURES CORP*W EXP 99/99/9990.00%$3,190100.0K
54BNCWWCEA INDUSTRIES INC*W EXP 02/11/2020.00%$2,988250.0K
55TG VENTURE ACQUISITION CORP*W EXP 08/15/2020.00%$2,960200.0K
56JEFFS BRANDS LTD*W EXP 08/26/2020.00%$2,58968.7K
57SRZNWSURROZEN INC*W EXP 08/01/2030.00%$1,44382.2K
58COLISEUM ACQUISITION CORP*W EXP 08/22/2020.00%$1,13328.3K
59NEXALIN TECHNOLOGY INC*W EXP 09/15/2020.00%$924105.0K
60TCBWFTC BIOPHARM HOLDINGS PLC*W EXP 02/10/2020.00%$61218.8K
61SELINA HOSPITALITY PLC*W EXP 10/27/2020.00%$426101.4K
62BRSWFBRUUSH ORAL CARE INC*W EXP 08/03/2020.00%$9814.4K
63RELATIVITY ACQUISITION CORP*W EXP 12/15/2020.00%$0100.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$42M19May 1, 202613F-HRchanges · EDGAR ↗
Q4 2025$25M18Feb 6, 202613F-HRchanges · EDGAR ↗
Q3 2025$628,2621Nov 4, 202513F-HRchanges · EDGAR ↗
Q2 2025$01Aug 7, 202513F-HRchanges · EDGAR ↗
Q1 2025$42M24May 13, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$353M67Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$340M79Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$245M68Aug 15, 202413F-HRchanges · EDGAR ↗
Q1 2024$253M72May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$147M66Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$192M72Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$132M68Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$180M91May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$197M94Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$273M134Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$250M127Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$299M118May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$363M133Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$381M124Nov 17, 2021RESTATEMENTchanges · EDGAR ↗
Q2 2021$431M135Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$360M124May 6, 202113F-HRchanges · EDGAR ↗
Q4 2020$266M98Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.